JP2017536369A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017536369A5 JP2017536369A5 JP2017527260A JP2017527260A JP2017536369A5 JP 2017536369 A5 JP2017536369 A5 JP 2017536369A5 JP 2017527260 A JP2017527260 A JP 2017527260A JP 2017527260 A JP2017527260 A JP 2017527260A JP 2017536369 A5 JP2017536369 A5 JP 2017536369A5
- Authority
- JP
- Japan
- Prior art keywords
- nrc
- compound according
- sulfur
- nitrogen
- oxygen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462082231P | 2014-11-20 | 2014-11-20 | |
| US62/082,231 | 2014-11-20 | ||
| PCT/US2015/061463 WO2016081679A1 (en) | 2014-11-20 | 2015-11-19 | Heteroaryl compounds as irak inhibitors and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017536369A JP2017536369A (ja) | 2017-12-07 |
| JP2017536369A5 true JP2017536369A5 (enExample) | 2018-12-20 |
| JP6787892B2 JP6787892B2 (ja) | 2020-11-18 |
Family
ID=54705914
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017527260A Active JP6787892B2 (ja) | 2014-11-20 | 2015-11-19 | Ｉｒａｋインヒビターとしてのヘテロアリール化合物及びその使用 |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US9790221B2 (enExample) |
| EP (1) | EP3221306B1 (enExample) |
| JP (1) | JP6787892B2 (enExample) |
| KR (2) | KR102683518B1 (enExample) |
| CN (1) | CN107108561B (enExample) |
| AR (1) | AR103138A1 (enExample) |
| AU (1) | AU2015349899B9 (enExample) |
| CA (1) | CA2964982C (enExample) |
| DK (1) | DK3221306T3 (enExample) |
| ES (1) | ES2772133T3 (enExample) |
| HR (1) | HRP20200179T1 (enExample) |
| HU (1) | HUE047586T2 (enExample) |
| IL (1) | IL252346B (enExample) |
| LT (1) | LT3221306T (enExample) |
| MX (1) | MX375625B (enExample) |
| NZ (1) | NZ730728A (enExample) |
| PL (1) | PL3221306T3 (enExample) |
| PT (1) | PT3221306T (enExample) |
| RS (1) | RS59974B1 (enExample) |
| RU (1) | RU2743718C2 (enExample) |
| SG (1) | SG11201702741SA (enExample) |
| SI (1) | SI3221306T1 (enExample) |
| WO (1) | WO2016081679A1 (enExample) |
| ZA (1) | ZA201702402B (enExample) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3286181T3 (da) | 2015-04-22 | 2021-04-06 | Rigel Pharmaceuticals Inc | Pyrazolforbindelser og fremgangsmåde til fremstilling og anvendelse af forbindelserne |
| CN108884077A (zh) * | 2016-02-25 | 2018-11-23 | 阿森纽荣股份公司 | 糖苷酶抑制剂 |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| CN110099899B (zh) | 2016-10-26 | 2024-01-02 | 里格尔药品股份有限公司 | 用作irak抑制剂的噁唑衍生物及其制备方法 |
| CN110234637B (zh) | 2016-10-26 | 2022-11-01 | 里格尔药品股份有限公司 | 用作irak抑制剂的吡唑酰胺化合物 |
| AU2017363313B2 (en) * | 2016-11-22 | 2021-06-24 | Dana-Farber Cancer Institute, Inc. | Inhibitors of interleukin-1 receptor-associated kinases and uses thereof |
| WO2018142393A1 (en) | 2017-02-01 | 2018-08-09 | Yissum Research Development Company Of The Hebrew | N1 -(4-(5-(cyclopropylmethyl)-1 -methyl-1 h-pyrazol-4-yl)pyridin-2-yl)cyclohexane-1,4-diamine derivatives and related compounds as ck1 and/or iraki inhibitors for treating cancer |
| TW202340194A (zh) | 2017-02-16 | 2023-10-16 | 美商基利科學股份有限公司 | 吡咯并[1,2-b]嗒𠯤衍生物 |
| EP3620457A4 (en) * | 2017-05-02 | 2021-01-06 | Korea Research Institute of Chemical Technology | PYRIMIDE-DERIVATIVE COMPOUND, OPTICAL ISOMER THEREOF, OR PHARMACEUTICAL SALT THEREOF AND COMPOSITION FOR THE PREVENTION OR TREATMENT OF TYRO-3 RELATED DISEASES THEREOF AS ACTIVE SUBSTANCE |
| WO2019008506A1 (en) * | 2017-07-03 | 2019-01-10 | Glaxosmithkline Intellectual Property Development Limited | N- (3- (2- (4-CHLOROPHENOXY) ACETAMIDO) BICYCLO [1.1.1] PENTAN-1-YL) -2-CYCLOBUTANE-1-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ATF4 INHIBITORS FOR THE TREATMENT OF CANCER AND OTHER DISEASES |
| IL301709B2 (en) * | 2017-08-09 | 2025-07-01 | Denali Therapeutics Inc | Compounds, compositions and methods |
| TW201920129A (zh) | 2017-09-01 | 2019-06-01 | 美商戴納立製藥公司 | 化合物、組合物及方法 |
| WO2019060693A1 (en) | 2017-09-22 | 2019-03-28 | Kymera Therapeutics, Inc. | CRBN LIGANDS AND USES THEREOF |
| MX2020003190A (es) | 2017-09-22 | 2020-11-11 | Kymera Therapeutics Inc | Degradadores de proteinas y usos de los mismos. |
| IL315310A (en) | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| EP3737666A4 (en) | 2018-01-12 | 2022-01-05 | Kymera Therapeutics, Inc. | PROTEIN DEGRADATION AGENTS AND ASSOCIATED USES |
| US11512080B2 (en) | 2018-01-12 | 2022-11-29 | Kymera Therapeutics, Inc. | CRBN ligands and uses thereof |
| US11292792B2 (en) | 2018-07-06 | 2022-04-05 | Kymera Therapeutics, Inc. | Tricyclic CRBN ligands and uses thereof |
| US12454520B2 (en) | 2018-07-06 | 2025-10-28 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| TWI721483B (zh) | 2018-07-13 | 2021-03-11 | 美商基利科學股份有限公司 | 吡咯并[1,2-b]嗒𠯤衍生物 |
| TWI727392B (zh) | 2018-08-13 | 2021-05-11 | 美商基利科學股份有限公司 | 噻二唑irak4抑制劑 |
| AU2019389174A1 (en) | 2018-11-30 | 2021-07-01 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| EP3924341A4 (en) | 2019-02-13 | 2022-11-02 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| CR20210426A (es) | 2019-02-13 | 2021-09-30 | Denali Therapeutics Inc | Compuestos, composiciones y métodos |
| PH12022500002A1 (en) | 2019-06-28 | 2023-04-03 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| US12558427B2 (en) | 2019-07-17 | 2026-02-24 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
| JP2022545542A (ja) | 2019-08-30 | 2022-10-27 | ライジェル ファーマシューティカルズ， インコーポレイテッド | ピラゾール化合物、その製剤並びに化合物及び／又は製剤を使用する方法 |
| WO2021119159A1 (en) | 2019-12-10 | 2021-06-17 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| CA3161878A1 (en) | 2019-12-17 | 2021-06-24 | Matthew M. Weiss | Irak degraders and uses thereof |
| EP4076524A4 (en) | 2019-12-17 | 2023-11-29 | Kymera Therapeutics, Inc. | IRAQ DEGRADERS AND USES THEREOF |
| TW202210483A (zh) | 2020-06-03 | 2022-03-16 | 美商凱麥拉醫療公司 | Irak降解劑之結晶型 |
| EP4161521A4 (en) | 2020-06-03 | 2024-07-10 | Kymera Therapeutics, Inc. | DEUTERED IRAQ DEGRADERS AND USES THEREOF |
| TW202241857A (zh) | 2020-12-18 | 2022-11-01 | 美商戴納立製藥公司 | 化合物之固體形式 |
| AR124547A1 (es) | 2020-12-30 | 2023-04-05 | Kymera Therapeutics Inc | Degradadores de irak y sus usos |
| WO2022174268A1 (en) | 2021-02-15 | 2022-08-18 | Kymera Therapeutics, Inc. | Irak4 degraders and uses thereof |
| WO2022187303A1 (en) | 2021-03-03 | 2022-09-09 | Rigel Pharmaceuticals, Inc. | A method for treating a disease or condition using a pyrazole compound or formulation thereof |
| WO2022217118A1 (en) * | 2021-04-09 | 2022-10-13 | Quanta Therapeutics, Inc. | Pyrimidine based ras modulators and uses thereof |
| CA3217792A1 (en) | 2021-05-07 | 2022-11-10 | Kymera Therapeutics, Inc | Cdk2 degraders and uses thereof |
| JP2024540080A (ja) | 2021-10-29 | 2024-10-31 | カイメラ セラピューティクス， インコーポレイテッド | Ｉｒａｋ４分解剤およびその合成 |
| CN116514769B (zh) * | 2022-01-21 | 2024-02-27 | 中国药科大学 | 4-羟基嘧啶-5-甲酰腙衍生物、制备方法、药物组合物和应用 |
| EP4472967A4 (en) | 2022-01-31 | 2026-04-15 | Kymera Therapeutics Inc | Iraqi Degradation Agents and Their Uses |
| CA3243798A1 (en) | 2022-02-09 | 2023-08-17 | Quanta Therapeutics, Inc. | Kras Modulators and Their Uses |
| ES3075943T3 (en) | 2022-03-23 | 2026-08-10 | Rigel Pharmaceuticals Inc | Pyrimid-2-yl-pyrazole compounds as irak inhibitors |
| WO2023230190A1 (en) | 2022-05-25 | 2023-11-30 | Quanta Therapeutics, Inc. | Pyrimidine based modulators and uses thereof |
| EP4680609A1 (en) | 2023-03-15 | 2026-01-21 | Quanta Therapeutics, Inc. | Kras modulators and uses thereof |
| CN117924102B (zh) * | 2024-01-23 | 2026-06-26 | 四川伊诺唯新生物医药有限公司 | 一种微管亲和力调节激酶抑制剂中间体的制备方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009026377A1 (en) | 2007-08-20 | 2009-02-26 | Board Of Regents, The University Of Texas System | Metal-containing polymers and uses thereof |
| WO2009054253A1 (ja) * | 2007-10-26 | 2009-04-30 | Konica Minolta Holdings, Inc. | 有機エレクトロルミネッセンス素子、表示装置及び照明装置 |
| AU2009279940B2 (en) | 2008-08-04 | 2014-01-16 | Merck Patent Gmbh | Novel phenylamino isonicotinamide compounds |
| US20120270237A9 (en) * | 2009-04-03 | 2012-10-25 | Cellzone AG | Methods for the identification of kinase interacting molecules and for the purification of kinase proteins |
| JP2011098948A (ja) * | 2009-06-25 | 2011-05-19 | Yamagata Promotional Organization For Industrial Technology | ビピリジン誘導体及びそれを含む有機エレクトロルミネッセンス素子 |
| WO2011084402A1 (en) * | 2009-12-21 | 2011-07-14 | Merck Sharp & Dohme Corp. | Tyrosine kinase inhibitors |
| JP5985473B2 (ja) * | 2010-07-13 | 2016-09-06 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | ＩＲＡＫ４モジュレーターとしてのピラゾロ［１，５ａ］ピリミジン及びチエノ［３，２ｂ］ピリミジン誘導体 |
| WO2013134415A1 (en) * | 2012-03-07 | 2013-09-12 | Vertex Pharmaceuticals Incorporated | Mannose derivatives for treating bacterial infections |
| JP6036804B2 (ja) * | 2012-03-22 | 2016-11-30 | コニカミノルタ株式会社 | 透明電極、電子デバイス及び有機エレクトロルミネッセンス素子 |
| BR112015000399A2 (pt) * | 2012-07-10 | 2017-06-27 | Ares Trading Sa | derivados de pirazolil pirimidina |
| ES2728403T3 (es) * | 2014-01-09 | 2019-10-24 | Merck Patent Gmbh | Derivados de pirimidin pirazolilo y su uso como inhibidores de IRAK |
-
2015
- 2015-11-19 LT LTEP15801650.1T patent/LT3221306T/lt unknown
- 2015-11-19 PT PT158016501T patent/PT3221306T/pt unknown
- 2015-11-19 AU AU2015349899A patent/AU2015349899B9/en active Active
- 2015-11-19 SG SG11201702741SA patent/SG11201702741SA/en unknown
- 2015-11-19 DK DK15801650.1T patent/DK3221306T3/da active
- 2015-11-19 CA CA2964982A patent/CA2964982C/en active Active
- 2015-11-19 MX MX2017006266A patent/MX375625B/es active IP Right Grant
- 2015-11-19 RS RS20200153A patent/RS59974B1/sr unknown
- 2015-11-19 KR KR1020237038922A patent/KR102683518B1/ko active Active
- 2015-11-19 EP EP15801650.1A patent/EP3221306B1/en active Active
- 2015-11-19 RU RU2017120274A patent/RU2743718C2/ru active
- 2015-11-19 WO PCT/US2015/061463 patent/WO2016081679A1/en not_active Ceased
- 2015-11-19 SI SI201531094T patent/SI3221306T1/sl unknown
- 2015-11-19 HR HRP20200179TT patent/HRP20200179T1/hr unknown
- 2015-11-19 JP JP2017527260A patent/JP6787892B2/ja active Active
- 2015-11-19 HU HUE15801650A patent/HUE047586T2/hu unknown
- 2015-11-19 PL PL15801650T patent/PL3221306T3/pl unknown
- 2015-11-19 NZ NZ730728A patent/NZ730728A/en not_active IP Right Cessation
- 2015-11-19 US US14/945,610 patent/US9790221B2/en active Active
- 2015-11-19 KR KR1020177015188A patent/KR20170086057A/ko not_active Ceased
- 2015-11-19 CN CN201580073060.9A patent/CN107108561B/zh not_active Expired - Fee Related
- 2015-11-19 ES ES15801650T patent/ES2772133T3/es active Active
- 2015-11-20 AR ARP150103793A patent/AR103138A1/es unknown
-
2017
- 2017-04-05 ZA ZA2017/02402A patent/ZA201702402B/en unknown
- 2017-05-17 IL IL252346A patent/IL252346B/en active IP Right Grant
- 2017-09-12 US US15/701,842 patent/US10030013B2/en active Active